Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OptiNose Inc OPTN

Healthcare
OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and... see more

Recent & Breaking News (NDAQ:OPTN)

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire 8 days ago

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

GlobeNewswire 11 days ago

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

GlobeNewswire May 10, 2024

Optinose Announces $55 Million Registered Direct Offering

GlobeNewswire May 9, 2024

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

GlobeNewswire April 25, 2024

Optinose to Present at the Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2024

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

GlobeNewswire March 15, 2024

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

GlobeNewswire March 7, 2024

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

GlobeNewswire February 29, 2024

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

GlobeNewswire January 18, 2024

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

GlobeNewswire December 6, 2023

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 22, 2023

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

GlobeNewswire November 9, 2023

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

GlobeNewswire October 27, 2023

Optinose to Present at the 2023 Cantor Global Healthcare Conference

GlobeNewswire September 22, 2023

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

GlobeNewswire August 10, 2023

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

GlobeNewswire July 27, 2023

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 16, 2023

Optinose to Present at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2023

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

GlobeNewswire May 11, 2023